Nucleics announces the establishment of Protigene, a fully-owned subsidiary of Nucleics. Protigene is focused on the commercialization of novel protein expression and purification technologies developed by Nucleics scientists. Protigene’s CEO, Dr Paul March, believes the creation of a separate subsidiary will enable Nucleics to capture the value from its protein expression and purification IP, while allowing Nucleics management to concentrate fully on the development of its Genomics products. Dr March says
“The protein [expression] technologies developed by Nucleics present a great opportunity, however, they do distract from [Nucleics] focus. Protigene gives [Nucleics] the resources to fully develop these new technologies. I am very excited about Protigene’s IP portfolio and believe strongly that we will provide the biomedical community with highly innovative products.”
For further information on Protigene or any of our protein expression and purification products please email us.